A Breakthrough Therapy Agent
Ibrance, a new class agent for treatment of metastatic breast cancer, has been approved in Russia, as announced at the press-conference at press-center of ITAR-TASS.
Talking to the participants, Ilya Timofeev, MD, PhD, Executive Director of the Russian Society of Clinical Oncology (RUSSCO), spoke on the issue of breast cancer and ways of solution.
Ibrance is a first-in-its-class inhibitor of cyclin-dependent kinases (CDK) 4/6 for treatment of metastatic breast cancer (mBC). It is recommended for treatment of the mows incident mBC type, known as +/HER2- mBC (70% of patients). Its effects are based on inhibition of cyclin-dependent kinases (CDK) 4/6 – molecules promoting growth of cancer cells, and is recommended as a combination with letrozole.
FDA assigned Ibrance a status of a breakthrough therapy agent based on preliminary clinical data demonstrating significant benefits of the drug over current methods of treatment. According to specialists, it has a potential for significant improvement of safety and efficacy of mBC treatment.